Praluent (Alirocumab)

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals, Federico II University

Conditions

HypercholesterolaemiaHypercholesterolemia

Phase 4

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

CompletedNCT02957682

Regeneron PharmaceuticalsHypercholesterolemia

Start: 2016-11-02End: 2020-03-05Updated: 2021-05-07

Unknown Phase

Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy

RecruitingNCT07375225

Federico II UniversityHypercholesterolaemia

Start: 2024-12-01End: 2027-12-01Target: 1500Updated: 2026-01-29